AbbVie’s atogepant meets late-stage goal in menstrual migraine study
AbbVie said its migraine treatment atogepant, branded as Qulipta in the U.S., reduced migraine days associated with the menstrual period in a late-stage study.
AbbVie said on Thursday that its migraine drug reduced migraine days linked to the menstrual period in a late-stage study. The treatment, chemically known as atogepant, is approved in the U.S. as Qulipta for migraine prevention in adults. The source text is truncated after stating that the drug met t…